Cargando…

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, urothelial, and renal cancer. Pancreatic ductal adenocarcinoma (PDAC) is one...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macherla, Shravanti, Laks, Shachar, Naqash, Abdul Rafeh, Bulumulle, Anushi, Zervos, Emmanuel, Muzaffar, Mahvish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274962/ https://www.ncbi.nlm.nih.gov/pubmed/30405053 http://dx.doi.org/10.3390/ijms19113505

Ejemplares similares

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
por: Marie, Mona A., et al.
Publicado: (2022)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
por: Pinato, David J., et al.
Publicado: (2020)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
por: Ricciuti, Biagio, et al.
Publicado: (2020)

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
por: Sehgal, Kartik, et al.
Publicado: (2021)

A Case of Warm Autoimmune Hemolytic Anemia Secondary to Epstein-Barr Virus Infection
por: Abidoye, Oluseyi, et al.
Publicado: (2022)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications
por: Amara, Suneetha, et al.
Publicado: (2022)

HSP90 as an emerging barrier to immune checkpoint blockade therapy
por: Tang, Daolin, et al.
Publicado: (2022)

Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer
por: Zhao, Jun, et al.
Publicado: (2019)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
por: Miljanic, Mihailo, et al.
Publicado: (2020)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)

Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model
por: Ghosh, Sanjana, et al.
Publicado: (2022)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
por: Cha, Edward, et al.
Publicado: (2013)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Hallmarks of response to immune checkpoint blockade
por: Cogdill, Alexandria P, et al.
Publicado: (2017)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers
por: Zhou, Min, et al.
Publicado: (2021)

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
por: Stromnes, Ingunn M, et al.
Publicado: (2022)

Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Mucinous Neoplasm
por: Poola, Shiva, et al.
Publicado: (2020)

Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
por: Mehra, Siddharth, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_raui5jt93pahccjgktbmbkh8nk